awarded by the EU 7 MEUR to HUS A consortium led by Helsinki University Hospital aims to unlock the full potential of real-world data collected in European cancer hospitals. This will support the delivery of new cancer treatments that are safer, more efficient and more personalized.
“Real-world data on the cost-effectiveness of treatments in real time are needed to implement value-based cancer care,” said senior medical director of oncology, project lead. Johanna Mattson.
The ONCOVALUE project aims to enable European cancer hospitals to collect real-world data (RWD) in an easy and timely manner. Continued development of treatments and improved outcomes require systematic collection and analysis of clinical data. Real-time, high-quality clinical data also helps regulatory and HTA agencies make decisions about the value of new cancer treatments. At best, the ONCOVALUE project could also enhance referral of effective new therapies. In addition, RWD can also identify patient groups that do not benefit from a particular therapy, helping to target treatment to those who have shown good response.
The consortium’s partners aim to develop new AI-based tools for automating clinical data collection and analysis. In addition, an end-to-end infrastructure will be built for her RWD reporting in health regulation and HTA decision-making. Additionally, ONCOVALUE has developed guidelines by 1) providing training for the collection and management of his RWD of high quality in European cancer centers and 2) the analysis of this data by HTAs and regulatory bodies. and methodology implementation.
ONCOVALUE opens the door to broad regulatory and HTA integration for RWD, leading to safer, more efficient and affordable treatments, technology and digital solutions for (personalized) cancer care . As such, OncoValue is well positioned to contribute to making cancer treatment more cost-effective and sustainable. Systematic collection and evaluation of patient-reported outcomes also leads to improved patient well-being. Subsequently, the long-term implementation of value-based cancer care in European cancer hospitals will help reduce the growing burden of cancer care in the EU and around the world.
The consortium consists of several leading European cancer hospitals and industry partners specializing in artificial intelligence, machine learning and communications. The preparation of the proposal was supported by Ttopstart, a consultancy firm specializing in EU financing.
ONCOVALUE Consortium: HUS Helsinki University Hospital (FI), Stichting Het Nederlands Kanker Instituut-Anton (NL), Elevate BV (NL), IQVIA Solutions BV (NL), Rigshospitalet Copenhagen University Hospital (DK), BC Platforms LTD OY (FI) , Siemens Healthcare GMBH (GER), Instituto Portugues de Oncologia do Porto (PT), Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IT), CIAOTech Srl (IT), TTOPSTART BV (NL).
Source: Helsinki University Hospital (HUS)